Advertisement

Topics

Sirion Therapeutics, Inc. Company Profile

00:39 EST 22nd November 2017 | BioPortfolio

Herpetic Keratitis is the number one infectious cause of corneal blindness in the U.S. Herpes simplex virus infections are very common, with nearly 60% of the US population showing evidence of infection by age five. Approximately 1% of infected patients develop ocular outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the US each year. After the primary infection, ocular HSV typically becomes latent until triggers such as stress, UV radiation, and hormonal changes reactivate the virus and cause recurrent outbreaks. Those recurrences account for an additional 28,000 cases per year in the US. The risk of blindness increases with the number and severity of recurrences, making prompt treatment imperative to limit corneal scarring and other more serious ocular complications caused by herpetic ulcers.


News Articles [532 Associated News Articles listed on BioPortfolio]

Sirion Partners with Vibalogics on Adeno-Associated Virus Services

NewsSirion Biotech and Vibalogics partner to offer complete adeno-associated virus (AAV) services. Sirion will provide specialist AAV technology, while Vibalogics will act as its production partner fo...

Sirion teams with Vibalogics to offer AAV services

German-based Sirion Biotech and Vibalogics are partnering up to offer adeno-associated virus services for the development of gene therapies.

SIRION Biotech and Vibalogics Partner

Will offer complete Adeno-Associated Virus (AAV) services

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, ...

http://dailystocktracker.com/register/ Cytori Therapeutics San Diego, Californiaheadquartered Cytori Therapeutics Inc.'s shares dropped 2.15%, closing Monday's trading session at $0.39. The stock ...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

Clinical Trials [121 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1173 Associated Companies listed on BioPortfolio]

SIRION Biotech GmbH

Founded in 2005, SIRION Biotech is a global leader in developing research and commercial grade viral vector solutions for industry and academic partners who are developing gene th...

Sirion GmbH

SIRION offers tools and services for RNAi expression and solutions for customized adenovirus-mediated gene delivery. SIRIONs proprietary Q-tech technology enables efficient RNAi driven gene silencing ...

SIRION

Nil

Tullis Health Investors

Tullis Health Investors (“THI”) manages a family of funds and investments, each focused exclusively on healthcare. THI has been a pioneer in healthcare-focused venture ...

Sirion Therapeutics, Inc.

Herpetic Keratitis is the number one infectious cause of corneal blindness in the U.S. Herpes simplex virus infections are very common, with nearly 60% of the US population showing evidence of infect...

More Information about "Sirion Therapeutics, Inc." on BioPortfolio

We have published hundreds of Sirion Therapeutics, Inc. news stories on BioPortfolio along with dozens of Sirion Therapeutics, Inc. Clinical Trials and PubMed Articles about Sirion Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sirion Therapeutics, Inc. Companies in our database. You can also find out about relevant Sirion Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record